Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru

  • Posted by: Biocon Biologics



Bengaluru, India; July 5, 2022:

“Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), has received a EU GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022.

The facility, spread across 340,000-square feet, will enhance our capabilities manifold to manufacture drug substance of our mAbs portfolio and will enable us to serve patients across the globe. This integrated, multi-product facility which also houses manufacturing suites, analytical testing laboratories and warehousing. Upon successful completion and qualification in 2021, it was awarded the Facility of the Year Award (FOYA) with a Honorable Mention, by the International Society for Pharmaceutical Engineering’s (ISPE).”

— Company Spokesperson, Biocon Biologics.

Author: Biocon Biologics